Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × isatuximab × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 8 Recurrence 1 Paraproteinemias 1 Neoplasms 1 Neoplasm, Residual 1 Lymphoproliferative Disorders 1 Immunoproliferative Disorders 1 Hematologic Neoplasms 1

Interventions

Cyclophosphamide 10 fludarabine 8 Rituximab 8 Dexamethasone 8 pembrolizumab 7 venetoclax 6 glofitamab 5 Lenalidomide 5 obinutuzumab 4 Etoposide 4 Calcium Dobesilate 4 pomalidomide 3 Temozolomide 3 Radiotherapy 3 Doxorubicin 3 Cytarabine 3 Carboplatin 3 zanubrutinib 2 tocilizumab 2 tisagenlecleucel 2 selinexor 2 ruxolitinib 2 ibrutinib 2 enzalutamide 2 dexamethasone acetate 2 dexamethasone 21-phosphate 2 carfilzomib 2 blinatumomab 2 abemaciclib 2 Vincristine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06832865 2026-03-12

ELISA in Relapsed/Refractory MM

Massachusetts General Hospital

Phase 2 Recruiting

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡